# A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

> **NCT05651711** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 726 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Rocatinlimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05651711
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-14
- **Primary completion:** 2024-06-05
- **Final completion:** 2024-08-27
- **Target enrollment:** 726 (ACTUAL)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05651711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05651711, "A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05651711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*